<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Journal of Advances in Medical and Biomedical Research</title>
<title_fa>Journal of Advances in Medical and Biomedical Research</title_fa>
<short_title>J Adv Med Biomed Res</short_title>
<subject>Medical Sciences</subject>
<web_url>http://journal.zums.ac.ir</web_url>
<journal_hbi_system_id>52</journal_hbi_system_id>
<journal_hbi_system_user>journal52</journal_hbi_system_user>
<journal_id_issn>1606-9366</journal_id_issn>
<journal_id_issn_online>2676-6264</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.30699/jambr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1404</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2025</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<volume>33</volume>
<number>162</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Genetic Insights Into Psoriasis Therapy: A Review of Polymorphisms in the Genes of Both TNF-α and the TNF Signaling Pathway on the Response to Anti-TNF-α</title>
	<subject_fa>Clinical Medicine</subject_fa>
	<subject>Clinical Medicine</subject>
	<content_type_fa>مقاله مروری</content_type_fa>
	<content_type>Review Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Tumor necrosis factor-alpha (TNF-&amp;alpha;) inhibitors are widely used as first-line treatments for moderate to severe plaque psoriasis, yet clinical responses vary considerably among patients despite their overall safety and efficacy. Genetic factors that influence the effectiveness of biologic therapies may contribute to this variability. This review, conducted between May and June 2024 using the Google Scholar and PubMed databases, examined studies exploring associations between genetic polymorphisms in TNF-&amp;alpha; and various genes within the TNF signaling pathway and patient responses to anti-TNF-&amp;alpha; therapy. A total of 20 relevant studies were identified, assessing polymorphisms in TNF-&amp;alpha; (&amp;minus;238/rs361525, &amp;minus;1031/rs1799964, &amp;minus;308/rs1800629, &amp;minus;857/rs1799724), TNF receptor genes such as TNFRSF1B (rs1061622), and additional related genes including TNFAIP3 (rs610604), IL1B (rs1143623 and rs1143627), FCGR2A (H131R/rs1801274), and FCGR3A (V158F/rs396991). Overall, these genetic variations demonstrate potential significance in modulating therapeutic responses to anti-TNF-&amp;alpha; agents in psoriasis. However, inconsistencies across existing studies highlight the need for larger, multi-center investigations to confirm their clinical relevance and support the integration of genetic markers into personalized treatment strategies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Psoriasis, Tumor Necrosis Factor Inhibitors, Pharmacogenetics, Polymorphism, Genetic</keyword>
	<start_page>1</start_page>
	<end_page>12</end_page>
	<web_url>http://journal.zums.ac.ir/browse.php?a_code=A-10-7400-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Abeer Kadhim</first_name>
	<middle_name></middle_name>
	<last_name>Jamaah</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>abeer.jomaa@copharm.uobaghdad.edu.iq</email>
	<code>5200319475328460087518</code>
	<orcid>0009-0005-2679-2477</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name> Fadya Y.</first_name>
	<middle_name></middle_name>
	<last_name>AL-Hamadani</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>fadia.jassem@copharm.uobaghdad.edu.iq</email>
	<code>5200319475328460087519</code>
	<orcid>5200319475328460087519</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name> Ali Fadhil</first_name>
	<middle_name></middle_name>
	<last_name>Al-Saadi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>al_saadi1968@yahoo.com</email>
	<code>5200319475328460087520</code>
	<orcid>0009-0008-4313-112X</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Dermatology and Venereology Center, Medical City, Baghdad, Iraq</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
